Please login to the form below

Not currently logged in
Email:
Password:

anticoagulants

This page shows the latest anticoagulants news and features for those working in and with pharma, biotech and healthcare.

Pharma sales help Bayer escape the worst from a bumpy 2017

Pharma sales help Bayer escape the worst from a bumpy 2017

Its pharma business was once again led by Bayer’s top-seller Xarelto, with sales of the oral anticoagulant rising 12.6% to 3.6bn, and eye drug Eylea, which was

Latest news

  • Bad news for Portola as CHMP considers Factor Xa drugs Bad news for Portola as CHMP considers Factor Xa drugs

    Portola Pharmaceuticals’efforts to secure approval for its novel oral anticoagulant (NOAC) and reversal agent in Europe have hit another snag. ... In the meantime, Boehringer Ingelheim’s rival NOAC Pradaxa (dabigatran) - which works by inhibiting

  • Joerg Moeller to head Bayer R&D after operational shake-up Joerg Moeller to head Bayer R&D after operational shake-up

    It will also highlight its plans to expand the use of novel oral anticoagulant (NOAC) Xarelto (rivaroxaban) into coronary and peripheral artery disease, along with new-generation anticoagulants in mid-phase

  • BMS’ Opdivo defies naysayers with healthy growth BMS’ Opdivo defies naysayers with healthy growth

    Outside oncology, BMS’top performer was novel oral anticoagulant Eliquis (apixaban), which grew 39% to $1.27bn, with Caforio claiming it is the most prescribed NOAC in the US, Japan and

  • J&J files would-be prostate cancer blockbuster in US J&J files would-be prostate cancer blockbuster in US

    That view was echoed by Jefferies Jeffrey Holford, who says J&J’s so-called TIRADE products - Tremfya (guselkumab) for psoriasis, cancer drug Imbruvica (ibrutinib), anticoagulant rivaroxaban (Xarelto), apalutamide, Darzalex (daratumumab)

  • Xarelto no better than aspirin in secondary stroke study Xarelto no better than aspirin in secondary stroke study

    Bayer and Johnson &Johnson have abandoned a 7, 000-patient trial pitting their novel oral anticoagulant (NOAC) Xarelto against aspirin for ischaemic stroke after conceding it will not meet its objectives. ... Patients with ESUS currently have limited

More from news
Approximately 17 fully matching, plus 204 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Canada. Nonetheless, new rival innovation in the anticoagulant market is already presenting challenges for Xarelto. ... This was largely thanks to Eliquis overtaking Bayer’s Xarelto as the leader in novel oral anticoagulants.

  • Digital disruption in market access Digital disruption in market access

    publication of the first direct oral anticoagulant technology appraisal, we are not yet there.

  • The pill branding The pill branding

    For example, if names suggest that the medication belongs to gastroenterology, although it is an anticoagulant, the name may be the source for medical errors.

  • Pharma deals in May 2015 Pharma deals in May 2015

    245. Isis/ Bayer. Licence agreement. Anticoagulant ISIS FXIRx for prevention of thrombosis in P2.

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Licence, option and collaboration. 164. Novartis/Aspen. Purchase of the heparin based anticoagulant Mono-Embolex, with sales of 68m in 2013.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics